[Comparative efficacy of the long-term use of long-acting nitroglycerin (sustak) and molsidomine after myocardial infarct complicated by heart failure].
Clinical and hemodynamic efficiency of long-term treatment with sustak and molsidomin was assessed in 56 patients following myocardial infarction complicated by circulatory insufficiency within 9 months after discharge from hospital. In spite of the same mechanism of action, long-term treatment with these drugs produces different clinical and hemodynamic effects. The efficiency of prolonged and continuous sustak treatment is shown to decline after 3 months, as reflected in weaker antianginal and hemodynamic effects of the drug. Molsidomin, on the contrary, retains its positive clinical and hemodynamic effects throughout 9 months of use. The long-term use of the peripheral vasodilator molsidomin effectively prevents heart failure in myocardial infarction survivors.
D000328:Adult; D000368:Aged; D003692:Delayed-Action Preparations; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D006439:Hemodynamics; D006801:Humans; D008875:Middle Aged; D008981:Molsidomine / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000150:complications* / Q000503:physiopathology; D005996:Nitroglycerin / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D008981:Molsidomine; D005996:Nitroglycerin
Sravnitel'naia éffektivnost' dlitel'nogo primeneniia prolongirovannogo nitroglitserina (sustaka) i molsidomina u bol'nykh, perenesshikh infarkt miokarda, oslozhnennyĭ nedostatochnost'iu krovoobrashcheniia.